ahb-137
Nucleic acidexperimental
Clinical trial activity
8 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Feb 28, 2023 (NCT05717686)
Timeline
Indications
Studied for
Mechanism of action
- Hepatitis B virusANTISENSE INHIBITOR
Hepatitis B virus antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07137910 | Phase 2 | Aug 27, 2025 | Government of China, Jinlin University |
| NCT07246889 | Phase 3 | Aug 12, 2025 | Government of China |
| NCT06993480 | Phase 2 | Jun 18, 2025 | Chongqing Medical University, Government of China |
| NCT07069569 | Phase 2 | May 30, 2025 | Capital Medical University, Government of China |
| NCT06829329 | Phase 2 | Dec 5, 2024 | Government of China |
| NCT06550128 | Phase 2 | Jul 5, 2024 | Government of China, Jinlin University, Southern Medical University |
| NCT06115993 | Phase 1 | Aug 3, 2023 | Government of China, Jinlin University |
| NCT05717686 | Phase 1 | Feb 28, 2023 | Government of China, University of Auckland |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 8 | 8 | 3 | 2023 |
| Jinlin University | Academic/Hospital | 3 | 0 | 2 | 2023 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Chongqing Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Southern Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Auckland | Academic/Hospital | 1 | 0 | 1 | 2023 |
6 organizations
Page 1 / 1